DBV Technologies S.A.

DBVTFSEC EDGAR

Biological Products, (No Diagnostic Substances)(I0)CIK: 1613780

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	$15.7M	$4.8M	$5.7M	$11.3M	$14.7M
Research and Development Expense	$60.2M	$75.5M	$70.3M	$101.6M	$115.1M
Operating Expenses	$92.2M	$101.5M	$104.3M	$170.1M	$185.7M
Operating Income (Loss)	-$76.4M	-$96.6M	-$98.6M	-$158.8M	-$171.0M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$72.7M	-$96.2M	-$98.2M	-$159.6M	-$171.4M
Income Tax Expense (Benefit)	$7.0K	$70.0K	-$381.0K	-$10.0K	$610.0K
Net Income (Loss) Attributable to Parent	-$72.7M	-$96.3M	-$97.8M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$183.0M	$246.5M	$146.7M	$272.2M	$271.7M
Assets, Current	$158.9M	$223.1M	$114.4M	$207.4M	$204.6M
Cash and Cash Equivalents, at Carrying Value	$141.4M	$209.2M	$77.3M	$193.3M	$140.6M
Inventory, Net	—	—	—	—	$2.3M
Liabilities	$42.8M	$52.1M	$47.4M	$66.8M	$78.5M
Liabilities, Current	$37.3M	$29.5M	$31.4M	$52.7M	$54.0M
Long-term Debt	—	—	$1.3M	$1.5M	$2.8M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$79.7M	-$55.7M	-$108.2M	-$165.6M	-$148.3M
Net Cash Provided by (Used in) Investing Activities	-$808.0K	-$100.0K	-$433.0K	-$2.9M	-$5.7M
Net Cash Provided by (Used in) Financing Activities	$6.8M	$194.1M	$274.0K	$149.5M	$207.6M
Payments to Acquire Property, Plant, and Equipment	$677.0K	$754.0K	$910.0K	$2.8M	$5.6M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)